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Abstract
Practical clinical trials (PCT) are randomized experiments under typical practice conditions with 
the aim of testing the “real life” benefits and risks of therapeutic interventions. Influential PCTs 
have been conducted in cardiology, oncology, and internal medicine. Psychotropic medications 
are widely and increasingly used in medical practice. This review examines recent progress in 
conducting PCTs in psychopharmacology. The January 2000 – October 2014 MEDLINE, Scopus, 
and ClinicalTrials.gov databases were searched for peer-reviewed publications of PCTs with at 
least 100 subjects per treatment arm. Most PCTs in psychiatry evaluated mental health services or 
psychosocial interventions rather than specific pharmacotherapies. Of 157 PCTs in psychiatry, 30 
(19%) were in psychopharmacology, with a median of 2 publications per year and no increase 
over the period of observation. Sample size ranged from 200 to 18,154; only 11 studies 
randomized 500 patients or more. Psychopharmacology PCTs were equally likely to be funded by 
industry as by public agencies. There were 10 PCTs of antidepressants, for a total of 4,206 patients 
(in comparison with at least 46 PCT of antihypertensive medications, for a total of 208,014 
patients). Some psychopharmacology PCTs used suicidal behavior, treatment discontinuation, or 
mortality as primary outcome, and produced effectiveness and safety data that have influenced 
both practice guidelines and regulatory decisions. PCTs can constitute an important source of 
information for clinicians, patients, regulators, and policy makers, but have been relatively 
underutilized in psychopharmacology. Electronic medical records and integrated practice research 
networks offer promising platforms for a more efficient conduct of PCTs.
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Introduction
Practical (or pragmatic) clinical trials (PCTs) are randomized studies conducted in practice 
settings to evaluate the effects of interventions delivered under typical community 
conditions rather than in tightly controlled research settings.1 PCTs complement and extend 
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the information provided by efficacy clinical trials, which test interventions under ideal 
experimental conditions by carefully selecting suitable patients, adopting a placebo control, 
and using intensive assessment batteries to detect statistically meaningful differences. 
“Phase III” efficacy trials have a major role in demonstrating the intrinsic pharmacological 
effects of medications, thus providing the data necessary for their registration and marketing 
approval. However, the same stringently controlled experimental conditions that maximize 
assay sensitivity limit the generalizability of the results to the patient population likely to 
receive the intervention in the community. In fact, only a fraction of patients typically 
referred for treatment are eligible for participating in efficacy trials, the majority being 
excluded for a variety of reasons, such as comorbid conditions, duration of illness, or 
symptom severity. In the case of antidepressants, for example, there are indications that 
placebo-controlled clinical trials, which are conducted on highly selected samples, tend to 
overestimate the effectiveness of these medications in clinical practice. 2, 3
Most clinical practice guidelines are still based on weak levels of evidence, and there is a 
recognized need to strengthen the evidence for clinical decisions.4 PCTs are meant to inform 
decision-making in clinical care by addressing the uncertainty that clinicians face at 
critically important decision points.1 Thus, the key features of a PCT include: a clinical 
dilemma for which there is genuine uncertainty on the best course of action (equipoise); a 
precisely formulated research hypothesis that directly addresses a practical medical decision; 
an easily measurable outcome of clinical significance (e.g., functional recovery, 
hospitalization, death, suicide attempt); randomized design; broad entry criteria to capture 
the typical clinical population likely to receive the intervention in usual care; practice 
setting; minimal clinician and patient research burden; and a sample size large enough to 
account for the heterogeneity of the participants.5 A PCT is designed to answer a single, 
clearly formulated research question by focusing on a major outcome of direct clinical 
relevance. While many patients are enrolled to ensure representativeness and statistical 
power, only few assessments are collected on each patient. Thus, successful PCTs tend to be 
“large simple trials”, a concept that applies to studies with many hundreds, if not thousands, 
of patients.
First advocated about 30 years ago, the PCT methodology has been widely applied to 
several areas of medicine.6 Highly influential PCTs have been conducted in cardiology, 
oncology, and internal medicine, addressing the management of myocardial infarct, stroke, 
hypertension, and breast cancer.7–12 The impetus to conducting PCTs in medicine continues, 
as the public health relevance of this type of research is being increasingly recognized.4,13
The application of the PCT methodology to psychiatry has been slow and more limited. A 
noteworthy example of PCT in psychopharmacology was reported in 1996,14 but it was not 
until the late 1990s that the need for PCTs in psychiatry began to be recognized. 5, 15–16 
PCTs are especially relevant to psychiatry because of common conditions, such as 
depression or anxiety, affecting millions of people, availability of a variety of treatments, 
both pharmacological and psychosocial, all with relatively small effect sizes, and uncertainty 
of treatment choice.
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In particular, pharmacotherapy has been an increasingly common treatment modality in 
mental health care. 17 As clinicians have a number of treatment options, decision making 
should rely on empirical evidence. The difference between two active treatments is usually 
small, but even a modest difference can be clinically important for major outcomes such as 
suicide, occupational dysfunction, or hospitalization. As pointed out by Peto and colleagues, 
the “medical importance of treatment effects that are only moderate in size implies the need 
for large-scale randomized evidence”. 6
This systematic review was conducted to examine the extent to which the PCT methodology 
has been applied to psychopharmacology. The aims were to identify PCTs with acceptable 
statistical power to detect treatment effects of psychiatric medications, and describe the PCT 
characteristics with respect to medications studied, sample size, outcome measures, and 
funding sources.
Methods
The Medline and Scopus databases were systematically searched for English language 
publications in the period January 2000 – October 2014, using the following key words: 
practical or pragmatic or large simple trials and psychiatry or mental health; effectiveness 
and randomized and psychiatry or mental health; primary care and mental health and 
treatment and randomized; practice setting and psychiatry and treatment and randomized. 
The search used clinical trial as a filter. In addition, the ClinicalTrial.gov database was 
searched using the key words psychiatric interventional randomized, and the bibliographic 
references of relevant publications were manually examined.
After removal of duplicates, the publication titles and abstracts were visually inspected, and 
articles were selected for further review. Reports were selected based on the following 
criteria: a) addressing a treatment of a mental health disorder or condition; b) assessing the 
treatment effect of a psychiatric medication or specified pharmacotherapy strategy; c) using 
a randomized design; d) including at least 100 randomized patients in each treatment arm; 
and e) meeting the key elements for a PCT design.
There is a continuum between purely efficacy and fully pragmatic clinical trials, with some 
studies having elements of both.18,19 For this review, the key PCT elements required for 
inclusion: 1) addressing a clinical issue of direct and practical importance for decision 
making in usual patient care; 2) using broadly inclusive entry criteria to ensure 
generalizability to the targeted clinical population; 3) following a simple protocol with 
minimal research burden for patients and clinicians; 4) testing interventions easily 
implementable in usual care; 5) using an easily measurable outcome of direct relevance to 
clinicians and patients; and 6) maintaining conditions of usual patient care. To be included, 
trials also had to have a sample size of at least 100 patients randomized to each study 
treatment arm, as smaller studies would not have sufficient statistical power to detect even a 
medium treatment effect size.
Excluded were: a) clinical trials of treatments of alcohol and substance abuse (including 
nicotine use), pain management, dementia, Parkinson, or other neurological disorders (but 
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studies testing treatment of psychiatric disorders, such as depression or psychosis, in the 
context of these conditions were included); b) clinical trials in which the specific effects of a 
pharmacotherapy could not be assessed because medications were part of a treatment 
“package”, together with other non-pharmacological interventions, and compared to usual 
care, so that the treatment effects of medication could not the disentangled from the overall 
effect of the “package”; and c) primary prevention clinical trials (studies of interventions to 
prevent relapse or recurrence were included).
Ten percent of the publications identified through the electronic search were independently 
inspected by another expert in clinical trials in order to assess inter-rater reliability. There 
was full agreement in 97% of the cases. Throughout the review process, in case of 
uncertainty in classifying a study as PCT, the publication was reviewed independently by 
the two experts (BV and JS) and, if needed, further discussed in order to achieve resolution. 
Trials conducted at university clinics were included if they had the key features of a 
pragmatic trial, with participation of community care settings, such as the Clinical 
Antipsychotic Trials of Intervention Effectiveness, which was conducted at 45 sites 
including private practices, Veteran Administration centers, and university clinics.20
For the purpose of comparison, selected recent meta-analyses of antihypertensive 
medications and relevant bibliographical references were searched in order to identify PCTs 
of antihypertensive medications with at least 100 patients randomized to each treatment 
group and conducted during the period 2000–October 2014.
Standard descriptive statistical methods were applied to the data.
Results
The initial search yielded a total of 2984 publications; an additional 19 were identified 
through manual reference review or other sources. After exclusion of duplicates, 2585 
publications were screened, and 1981 excluded as not meeting initial selection criteria 
(Supplemental Figure 1). Of the remaining studies, 230 were excluded for lacking key 
elements of a PCT and 217 for having a sample size per treatment group below 100. Of the 
remaining 157 PCTs, 72 (46%) tested services interventions (e.g., collaborative care models 
in primary care) rather than a specific treatment, 52 (33%) tested psychosocial interventions, 
and 3 (2%) tested other non-pharmacological interventions (i.e., physical exercise, massage 
therapy) (Supplemental Figure 2). The remaining 30 (19%) PCTs were in 
psychopharmacology (Table 1, Supplemental Table 1).20–49
The number of PCTs in psychopharmacology published ranged from 0 to 5 (median 2) per 
year, with no increase over the period of observation (Figure 1). Medications studied 
included antipsychotics (16 studies), antidepressants (10 studies), mood stabilizers (3 
studies), and an antianxiety agent (1 study). Cumulatively, a total of 32,556 patients were 
randomized in the 30 PCTs. Study sample size ranged from 200 to 18,154, with a median of 
387. Only 10 PCTs enrolled 500 or more patients. The time needed for trial completion 
ranged from 6 to 72 months, with a mean of 29.1 months and a median of 32 months (Table 
1).
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Of the 30 PCTs, 16 tested antipsychotic medications, having a sample size between 215 and 
18,154 (median 524, mean 3,214 ± SD 7,535), for a total of 27,315 randomized patients; 3 
PCTs had a sample size above 1,000. Ten PCTs tested antidepressant medications, having a 
sample size between 208 and 727 (median 401, mean 420± SD 185), for a total of 4,206 
randomized patients; none had a sample size above 1,000. As a comparison, primary reports 
of 46 PCTs of antihypertensive medications published in 2000–2014 were identified by 
searching recent meta-analyses.50–56 These 46 PCTs had a sample size between 250 and 
33,357 (median 1,700, mean 4,728±SD 5,985), for total of 208,014 randomized patients; 33 
(72%) had a sample size above 1,000.
A wide range of comparison groups were used in the 30 psychopharmacology PCTs, most 
commonly another medication, but also psychotherapy or combination of medication and 
psychotherapy trials. A few studies also included placebo to mask treatment assignment and 
ensure assay sensitivity of the trial. Most (N=20) PCTs were open-label, meaning that both 
clinicians and patients were aware of the treatment condition. A few studies used masked 
raters to assess outcome as a way of minimize ascertainment biases.
For 15 PCTs (50% of the cases), the primary outcome was the incidence or time to a specific 
event that was deemed to be clinically significant, including remission, treatment 
discontinuation, need for a treatment change, falling asleep, emergence of delirium, death, 
suicidality episode, or hospitalization. In the other cases, the primary outcome was 
symptomatic improvement measured with a disorder-specific clinical rating scale (e.g., 
Hamilton Depression Rating Scale), global improvement (e.g., using the Clinical Global 
Impression Scale), or change in quality of life (Table 1)
Of the 30 psychopharmacology PCTs, a statistically and clinically significant difference 
between treatments was reported in 16 studies, allowing a conclusion of superiority of one 
treatment over the other to be drawn. In the other 14 studies, no difference was detected, 
leading the authors to conclude that there was no advantage, or disadvantage, of one 
treatment over the other.
Most of the 30 PCTs were conducted in either the U.S.A. or the U.K. PCTs were equally 
likely to be funded by industry (12 studies) as by public agencies (11 studies) (Table 1).
Discussion
The concept of PCT was first introduced into psychiatry about 15 years ago as an important 
source of practical information to complement and expand the data from traditional efficacy 
trials. 6 This systematic review identified 157 psychiatric PCTs, with a minimum sample 
size of 100 patients per treatment group, reported between January 2000 and October 2014. 
Of these, 30 (19%) were in psychopharmacology. Most PCTs in psychiatry tested the 
effectiveness of mental health services or psychosocial interventions, rather than specific 
pharmacological agents. This may not be surprising as a number of decision points in 
clinical practice relate to choice of services. No trend towards an increase in the number of 
psychopharmacology PCTs was detected. Thus, despite the widespread use of psychotropic 
medications, the application of the PCT methodology to addressing pharmacotherapy 
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decision-making remains rather infrequent. Furthermore, of the identified 30 PCT, only one 
third had a total sample size of 500 or more, indicating that psychopharmacology has had 
very few “large simple trials”.
The underutilization of PCT in psychopharmacology is most evident in the case of 
antidepressants. Depressive disorders are the leading cause of burden of disease in middle- 
and high-income countries, followed by ischemic heart disease and cerebrovascular 
disease.57 Still, there were 20 PCTs of antidepressants for a cumulative number of less than 
5,000 patients vis-à-vis at least 46 PCTs of antihypertensive medications for a cumulative 
number of more than 200,000 patients. More than two-thirds of the antihypertensive PCTs 
had a sample size greater than 1,000 as compared with none of the antidepressant PCTs.
On a more positive note, the review shows that psychopharmacology PCTs can be 
successfully conducted and provide important information. Some of the identified PCTs 
have addressed critical issues of psychiatric care, such as the choice of antipsychotic20,32 or 
antidepressant medication,29,30,42 prevention of suicide,25 or major safety concerns.43 The 
largest PCT enrolled more than 18,000 patients with schizophrenia, 43 a sample size 
comparable to that of the PCTs conducted in cardiology and oncology. This study was 
requested by the Food and Drug Administration to inform on the safety of ziprasidone, and 
the finding that this medication did not increase mortality had important both clinical and 
regulatory implications. It is noteworthy that most pragmatic trials evaluated the 
effectiveness and safety of antipsychotic medications, which are typically used to treat most 
severe forms of mental illness.
It seems critical that future PCTs should include enough patients to ensure adequate 
statistical power to address the study hypothesis in a definitive way. Given that, by 
definition, PCTs have broadly inclusive entry criteria in order to represent the diversity of 
community patients, and that the difference between treatments is likely to be of a small 
effect size, large sample sizes are necessary. This is especially relevant to interpreting 
studies that do not show the superiority of one treatment over another. In fact, lack of a 
difference in a study designed as a superiority trial (i.e., an experiment attempting to reject a 
null hypothesis of no difference) does not demonstrate equivalence (i.e., it can only reject 
but not accept the null hypothesis). “Negative trials” (i.e., trials with no treatment 
difference) and “failed trials” (i.e., trials without assay sensitivity as indicated by lack of 
effect of the active comparator) are extremely common in psychopharmacology, accounting, 
for example, at least half of the antidepressant placebo-controlled trials. 58 It is critical that 
PCTs avoid this unfortunate situation. A large sample size and, when appropriate, a non-
superiority or equivalence design may be the best approach to protecting the interpretation 
of the results.
Looking to the future, a number of developments seem to favor the expansion of PCTs. 
Following dissatisfaction with traditional clinical trials, which are seen as lengthy, costly, 
and of uncertain ecological validity,59,60 there is increased interest in the PCT as an essential 
tool to advance evidence-based medicine, including psychiatric care.61 Attention has been 
brought to the need to decrease the administrative and regulatory complexities the slow the 
conduct of clinical trials. 62,63 For example, the current bioethical framework for clinical 
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trials was set up to address traditional efficacy trials, which are conducted in research 
settings and evaluate novel treatments. For this type of studies, a rigorous separation 
between research and clinical care functions has been advocated under the tenet that 
research is essentially aimed at generating new generalizable knowledge and not at 
improving the condition of the individual research participants.64 But PCTs are conducted in 
practice settings and compare interventions of known efficacy that are delivered by 
clinicians, thus blurring the difference between research and clinical care. Thus, a different 
framework is needed to ensure appropriate protection of research participants in a context of 
a close interface, rather than separation, of clinical and research components.65,66
From the funding perspective, the recently constituted Patient Oriented Outcome Research 
Institute (PCORI) in the U.S.A., has the mission of funding clinical research of direct 
relevance to patient care and will provide an important resource for conducting PCTs in 
medicine, including psychiatry.67 In particular, the development of PCORnet and 
psychiatric research networks, such as the Mental Health Research Network, provide 
infrastructure for large PCTs.68 Currently, the only psychiatric component of PCORnet is 
the Mood Patient Powered Research Network that is planning to launch PCTs in patients 
with major depressive and bipolar disorders.69 Electronic medical records are becoming 
more common and can facilitate the collection and transfer of clinical data thus making 
easier and less expensive to conduct PCTs.70
More speculatively, a methodological challenge is how to enrich the traditional PCT design 
in order to make it more relevant to the age of personalized medicine while maintaining its 
key features (i.e., practice setting, broadly, representative sample, and low research burden 
on patients and clinicians). A limitation of current PCTs is that they inform at the group 
mean level. By estimating average treatment response rate, they provide generally useful 
parameters such as the number needed to treat. But they do not contribute to identifying a 
priori treatment responders or explaining why non-responders did not improve. In fact, 
PCTs are, by current definition, the very opposite of such “explanatory trials”, as they 
collect only the data necessary to answer the primary question of the study. Personalized 
medicine, on the other hand, aims at tailoring of treatment to the specific characteristics and 
needs of individual patients. To this end, the research approach of personalized medicine is 
to target the treatment to the precisely identified pathophysiological processes that underlie 
the clinical manifestations of the disease.71 Technological advances may bridge this gulf 
between PCTs and personalized medicine. Collection of genetic material can be easily 
accomplished in practice settings. Availability of electronic medical records linked to PCT 
participants can provide access to detailed information without requiring intensive data 
collection in the PCT.72 It may not be inconceivable to foresee “large complex trials” in a 
not too distant future.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Practical clinical trials in psychiatry 2000–2014 by publication year1
1
 Through October 2014; not included in this figure are 3 trials testing alternative 
interventions (2 physical exercise in 2012 and one massage therapy in 2007)
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Table 1
Characteristics of Identified Psychopharmacology Practical Clinical Trials (PCTs)
Total N of PCTs 30
Sample size (total N): lowest-highest 200–18,154
median 387
Total sample size (N of PCT with N=200–499 19
N=500–1,000 8
N>1000 3
Study design: N of PCTS open-label 20
double-blind 9
single-blind 1
Primary outcome: specific eventa 15
symptom improvement 7
global improvement 5
othersb 3
Duration of PCT (months) mean ± SD 29.1 ± 17.5
median 32
Geographical area Americas 12
Europe 12
India 3
Intercontinental 3
Medication studied (N of trials) antipsychotic 16
antidepressant 10
mood stabilizer 3
other 1
Reporting a statistically significant difference between treatments Yes 16
No 14
Funding source (N of trials) Industry 12
Public 11
Private non-profitc 5
Mixed 2
aSpecific event included: treatment discontinuation (3), illness remission (3), need for treatment change (2), falling asleep (3), delirium (1), 
mortality (1), suicidal episode (1), hospitalization/crisis (1).
bQuality of life (1), metabolic status (1), total time free of symptoms (1).
c
Including institutional academic or hospital funds.
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